Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Exagen Inc. publishes a filing, an earnings call transcript or a press release.

Get XGN alerts

About Jeffrey G. Black

Jeffrey G. Black is recorded as CFO at Exagen Inc. (XGN) and CFO at Boston Scientific Corp (BSX). The newest filing on record that lists Jeffrey G. Black as CFO at Exagen Inc. (XGN) is dated April 27, 2026. Jeffrey G. Black was last confirmed as CFO at Standard Biotools Inc. (LAB) in a filing dated April 30, 2025. Earlier roles on record: CFO at Alphatec Holdings, Inc. (ATEC) until April 18, 2021 and CFO at Standard Biotools Inc. (LAB) until August 31, 2024. Exagen Inc. reported in an 8-K filed August 2, 2024 that Jeffrey G. Black was appointed Chief Financial Officer and principal financial officer for SEC reporting purposes, effective September 1, 2024. Standard Biotools Inc. reported in an 8-K filed July 31, 2024 that Jeffrey G. Black resigned as Senior Vice President and Chief Financial Officer, effective August 31, 2024. The same filing states: “Mr. Black’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, and was driven by his desire to accept an opportunity at another public company.” Standard Biotools Inc. reported in an 8-K filed May 15, 2023 that Jeffrey G. Black was appointed Senior Vice President and Chief Financial Officer, effective May 15, 2023. Equibles holds 5 filed executive changes naming Jeffrey G. Black; each is listed under recent activity with its source filing. The proxy statement of Exagen Inc. reports total compensation of $746,190 for Jeffrey G. Black in fiscal 2025, including a base salary of $465,000. Disclosed compensation is on record for 6 fiscal years. Jeffrey G. Black has spoken on 8 earnings calls across 3 companies, most recently for Exagen Inc. on November 10, 2026. Those appearances were for Exagen Inc. (XGN), Standard Biotools Inc. (LAB) and Alphatec Holdings, Inc. (ATEC). Exagen Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Boston Scientific Corp is classified in the Medical Devices industry within the Healthcare sector. Other companies whose calls Jeffrey G. Black spoke on are classified in the Healthcare sector. Other leadership on record at Exagen Inc. includes John Aballi (CEO, CFO and Board Member), Tina S. Nova (Chairman), Mark Hazeltine (COO) and 7 others.

“On July 25, 2024, Exagen Inc. (the “Company”) appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.”
Exagen Inc. Form 8-K, filed August 2, 2024 · Read the filing
“On July 26, 2024, Jeffrey Black resigned as the Senior Vice President and Chief Financial Officer (serving as the principal financial and accounting officer) of Standard BioTools Inc. (the "Company"), effective as of August 31, 2024.”
“Mr. Black’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, and was driven by his desire to accept an opportunity at another public company.”
Standard Biotools Inc. Form 8-K, filed July 31, 2024 · Read the filing

Jeffrey G. Black on recent calls

“As John just highlighted, our third quarter results reflect another solid quarter of execution across the business. Starting with third quarter revenue, we generated $18.4 million, an increase of 7%.”
CFO, Q3 2026 Earnings Call ·
“As John just highlighted, our second quarter results reflect another strong quarter of execution across the business. We achieve record top-line performance, driven by record testing volume in trailing 12-month ASP, and a record contribution from our pharma services offering.”
CFO, Q2 2026 Earnings Call ·
“In 2025, our team continued to structurally reposition the business for profitable long-term growth, and we're pleased to see that work translate into financial results.”
CFO, Exagen Inc. Q4 FY2025 Earnings Call ·
“As John mentioned, we delivered another strong quarter, highlighted by our third consecutive quarter of volume growth, continued ASP expansion and a balance sheet that we expect secures our runway to positive free cash flow.”
CFO, Exagen Inc. Q3 FY2025 Earnings Call ·
“As John mentioned, we delivered another record revenue quarter. It was also a busy quarter as we executed on initiatives to shore up the balance sheet. As we discussed during the last earnings call, we refinanced our debt and added additional tranches that we can utilize at our option.”
CFO, Exagen Inc. Q2 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Exagen Inc.

Leadership on record at Boston Scientific Corp

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Exagen Inc. (XGN) $465,000 $746,190
2024 Exagen Inc. (XGN) $141,536 $1,021,036
2023 Exagen Inc. (XGN) — —
2023 Standard Biotools Inc. (LAB) $259,375 $1,492,297
2022 Standard Biotools Inc. (LAB) — —
2019 Alphatec Holdings, Inc. (ATEC) $350,000 $1,941,939
2018 Alphatec Holdings, Inc. (ATEC) $350,000 $926,925

Recent activity